This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Pirgon, O. Articles by Atabek, M. E. Search for Related Content PubMed PubMed Citation Articles by Pirgon, O. Articles by Atabek, M. E. Social Bookmarking                   What's this?

Proton Magnetic Resonance Spectroscopy Findings and Clinical Effects of Montelukast Sodium in a Case With Sjögren-Larsson Syndrome

Department of Pediatrics, Section of Pediatric Endocrinology

Kursad Aydin, MD

Department of Pediatrics, Section of Pediatric Neurology

M. Emre Atabek, MD

Department of Pediatrics, Section of Pediatric Endocrinology, Faculty of Medicine, Selcuk University, Konya, Turkey

Sjögren-Larsson syndrome is a rare hereditary metabolic disorder characterized by congenital ichthyosis, mental retardation, and spastic diplegia or tetraplegia. This genetic disease is caused by fatty acid aldehyde dehydrogenase deficiency, leading to an accumulation of long-chain alcohols. The role of enzyme in the degradation of leukotrienes paved the way to the development of a new therapeutic strategy for Sjögren-Larsson syndrome, leukotriene antagonists. We describe a 3-year-old boy with Sjögren-Larsson syndrome who had a lipid peak on proton magnetic resonance spectroscopy despite normal findings on cerebral magnetic resonance imaging. He benefited from treatment with montelukast sodium, especially with respect to the agonizing pruritus.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?